Randomized Controlled Trials in Neuroendocrine Tumors

John C. McAuliffe, Edward M. Wolin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Understanding of neuroendocrine tumors has increased greatly in the last 2 decades. Along with this, the prevalence of neuroendocrine tumors has increased because of the ubiquitous use of cross-sectional imaging, improved endoscopic screening, and the indolent nature of the disease. Up to 35% of patients have symptoms at the time of diagnosis, whereas the others have occult disease. Neuroendocrine tumors are a diverse group of malignancies with unique clinical courses. This article critically reviews the most important randomized controlled trials for neuroendocrine tumors and introduces a few awaiting completion.

Original languageEnglish (US)
JournalSurgical Oncology Clinics of North America
DOIs
StateAccepted/In press - 2017

Fingerprint

Neuroendocrine Tumors
Randomized Controlled Trials
Neoplasms

Keywords

  • Carcinoid
  • Clinical trial
  • Neuroendocrine tumor
  • Somatostatin

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Randomized Controlled Trials in Neuroendocrine Tumors. / McAuliffe, John C.; Wolin, Edward M.

In: Surgical Oncology Clinics of North America, 2017.

Research output: Contribution to journalArticle

@article{e6e02c9d4ffd4d2e95bfa006851f780c,
title = "Randomized Controlled Trials in Neuroendocrine Tumors",
abstract = "Understanding of neuroendocrine tumors has increased greatly in the last 2 decades. Along with this, the prevalence of neuroendocrine tumors has increased because of the ubiquitous use of cross-sectional imaging, improved endoscopic screening, and the indolent nature of the disease. Up to 35{\%} of patients have symptoms at the time of diagnosis, whereas the others have occult disease. Neuroendocrine tumors are a diverse group of malignancies with unique clinical courses. This article critically reviews the most important randomized controlled trials for neuroendocrine tumors and introduces a few awaiting completion.",
keywords = "Carcinoid, Clinical trial, Neuroendocrine tumor, Somatostatin",
author = "McAuliffe, {John C.} and Wolin, {Edward M.}",
year = "2017",
doi = "10.1016/j.soc.2017.05.012",
language = "English (US)",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Randomized Controlled Trials in Neuroendocrine Tumors

AU - McAuliffe, John C.

AU - Wolin, Edward M.

PY - 2017

Y1 - 2017

N2 - Understanding of neuroendocrine tumors has increased greatly in the last 2 decades. Along with this, the prevalence of neuroendocrine tumors has increased because of the ubiquitous use of cross-sectional imaging, improved endoscopic screening, and the indolent nature of the disease. Up to 35% of patients have symptoms at the time of diagnosis, whereas the others have occult disease. Neuroendocrine tumors are a diverse group of malignancies with unique clinical courses. This article critically reviews the most important randomized controlled trials for neuroendocrine tumors and introduces a few awaiting completion.

AB - Understanding of neuroendocrine tumors has increased greatly in the last 2 decades. Along with this, the prevalence of neuroendocrine tumors has increased because of the ubiquitous use of cross-sectional imaging, improved endoscopic screening, and the indolent nature of the disease. Up to 35% of patients have symptoms at the time of diagnosis, whereas the others have occult disease. Neuroendocrine tumors are a diverse group of malignancies with unique clinical courses. This article critically reviews the most important randomized controlled trials for neuroendocrine tumors and introduces a few awaiting completion.

KW - Carcinoid

KW - Clinical trial

KW - Neuroendocrine tumor

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=85026781426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026781426&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2017.05.012

DO - 10.1016/j.soc.2017.05.012

M3 - Article

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

ER -